ChemoCentryx is a biopharmaceutical company commercializing and developing medications for inflammatory and autoimmune diseases and cancer. It focuses on orphan and rare diseases, chronic kidney disease, immuno-oncology, and other inflammatory diseases. The company offers TAVNEOS, adjunctive treatment for adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis.